Skip to main content
Retour
CYTK logo

Cytokinetics, Incorporated

Qualité des données : 100%
CYTK
NASDAQ Healthcare Biotechnology
60,02 €
▼ 0,93 € (-1,53%)
Cap. Boursière : 7,39B
Fourchette du Jour
59,03 € 60,54 €
Fourchette 52 Semaines
29,31 € 70,98 €
Volume
2 105 334
Moyenne 50J / 200J
63,71 € / 53,26 €
Clôture Précédente
60,95 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -9,4 0,3
P/B 2,9
ROE % 3,7
Net Margin % -891,6 3,8
Rev Growth 5Y % 5,7 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
92,27 € +53.7%
Low: 69,00 € High: 136,00 €
BPA Prévisionnel
-6,41 €
CA Est.
92 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 4,37 €
3,31 € – 7,68 €
2,2 B 12
FY2029 0,85 €
0,64 € – 1,49 €
1,4 B 8
FY2028 -2,36 €
-4,70 € – -0,90 €
790 M 14

Points Clés

Revenue grew 5,74% annually over 5 years — modest growth
Negative free cash flow of -534,82M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 370,82%

Croissance

Revenue Growth (5Y)
5,74%
Revenue (1Y)376,56%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-73,52%
Net Margin-891,60%
Op. Margin-695,44%

Sécurité

Debt / Equity
N/A
Current Ratio4,53
Interest Coverage-5,89

Valorisation

P/E Ratio
-9,42
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 376,56% Revenue Growth (3Y) 241,93%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5,74% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 88,04M Net Income (TTM) -784,96M
ROE N/A ROA -55,10%
Gross Margin 88,50% Operating Margin -695,44%
Net Margin -891,60% Free Cash Flow (TTM) -534,82M
ROIC -73,52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,53
Interest Coverage -5,89 Dividend Yield 0,00%
Valuation
P/E Ratio -9,42 P/B Ratio N/A
P/S Ratio 83,97 PEG Ratio -0,40
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 7,39B Enterprise Value 7,79B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 88,04M 18,47M 7,53M 94,59M 70,43M
Net Income -784,96M -589,53M -526,24M -388,96M -215,31M
EPS (Diluted) -6,54 -5,26 -5,45 -4,33 -2,80
Gross Profit 77,91M -320,93M -322,59M -146,23M -89,51M
Operating Income -612,26M -536,25M -496,21M -324,20M -186,31M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,42B 1,40B 824,32M 1,01B 841,32M
Total Liabilities 2,08B 1,54B 1,21B 1,12B 597,46M
Shareholders' Equity -659,63M -135,37M -386,32M -107,90M 243,86M
Total Debt 1,28B 788,68M 755,77M 750,30M 269,93M
Cash & Equivalents 882,22M 94,86M 113,02M 65,58M 112,67M
Current Assets 916,98M 1,11B 628,05M 795,19M 535,67M
Current Liabilities 202,45M 179,67M 102,68M 84,62M 71,86M